Compare Sanofi SA (SNY) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Materials Select Sector SPDR Fund — how do they compare? Sanofi SA trades at $43.12 (market cap $103.41B), while Materials Select Sector SPDR Fund trades at $51.45. The key difference: Sanofi SA pays a 5.65% dividend while Materials Select Sector SPDR Fund pays none, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | XLB | |
|---|---|---|
Market Cap | $103.41B | — |
Sector | Health | — |
52-Week High | $52.34 | $53.67 |
52-Week Low | $41.33 | $42.23 |
Enterprise Value | $123.44B | — |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
XLB trades at $51.95, down 0.93% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The materials sector ETF benefits from AI infrastructure trends and strong Q2 earnings momentum across the sector. Recent news highlights potential opportunities in materials as investors rotate toward tangible assets.
The outlook for XLB appears constructive given sector tailwinds from infrastructure spending and AI buildout, though cyclical recovery may be partially priced in. Key risks include materials price volatility and geopolitical supply chain pressures. Analyst sentiment is mixed with some viewing current levels as fully valued after recent sector rebound.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
